This is a working overview of purity certificate, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Meyer even criticized Hutchinson publicly, prompting a meeting between the three men and team owner August Busch Jr., in which Hutchinson appealed to the owner to "Let me alone to do my job." "That thing with Mizell in Brooklyn, I just wanted to get him over a hump," Hutchinson later explained. Through July 27, Mizell had a 5.32 ERA, but his control started to improve in the middle of the year. Called on for a start on July 29, he held the Pirates to two hits in a 4–0 shutout victory. Thereafter, most of his appearances would be starts. With the second-place Cardinals trailing the NL-leading Milwaukee Braves on August 18, Mizell threw a four-hit shutout, helping the Cardinals sweep a doubleheader and remain in the pennant race. His ERA after July 27 was 2.54. In 33 games (21 starts), he had an 8–10 record, a 3.74 ERA, 87 strikeouts, and 51 walks in 149+1⁄3 innings. Over the 1957–58 offseason, Mizell practiced throwing with a steel ball. He arrived early to 1958 spring training, claiming to have lost 12 pounds from the previous spring. He had a 3–6 record entering June 21, but from that date through July 12, he won four straight games. On June 25, though he walked five batters, he allowed just three hits and one unearned run in a 3–1 victory over the Pirates. Then, on July 12, he threw a shutout in a 2–0 win over the Pirates. He had a pitching duel against Joe Nuxhall of Cincinnati in the first game of a doubleheader on September 1; Mizell prevailed 1–0, setting an NL record for most walks in a shutout with nine.
sex linkage The presence of a particular gene or DNA sequence on a sex chromosome (in mammals either the X chromosome or the Y chromosome) rather than on an autosome; these genes are said to be sex-linked. Expression of sex-linked genes varies by organism depending on the mechanism of sex determination and the types of sex chromosomes present, but the associated phenotypes often exclusively appear in either the homogametic or heterogametic sex.
In 1952, L. V. Radushkevich and V. M. Lukyanovich published clear images of 50-nanometre diameter tubes made of carbon in the Journal of Physical Chemistry of Russia. This discovery was largely unnoticed, as the article was published in Russian, and Western scientists' access to Soviet press was limited during the Cold War. Monthioux and Kuznetsov mentioned in their Carbon editorial: The fact is, Radushkevich and Lukyanovich [...] should be credited for the discovery that carbon filaments could be hollow and have a nanometre-size diameter, that is to say for the discovery of carbon nanotubes. In 1976, Morinobu Endo of CNRS observed hollow tubes of rolled up graphite sheets synthesised by a chemical vapour-growth technique. The first specimens observed would later come to be known as single-walled carbon nanotubes (SWNTs). Endo, in his early review of vapor-phase-grown carbon fibers (VPCF), also reminded us that he had observed a hollow tube, linearly extended with parallel carbon layer faces near the fiber core. This appears to be the observation of multi-walled carbon nanotubes at the center of the fiber. Mass-produced MWCNTs are strongly related to the VPGCF developed by Endo. In fact, they call it the "Endo process", out of respect for his early work and patents. In 1979, John Abrahamson presented evidence of carbon nanotubes at the 14th Biennial Conference of Carbon at Pennsylvania State University. The conference paper described carbon nanotubes as carbon fibers that were produced on carbon anodes during arc discharge.
Three people were killed in a Russian missile attack on Dnipro. In Russia, the governor of Tambov Oblast claimed that an oil depot was set on fire by a drone strike. Seven Ukrainian drones struck the Novolipetsk Metallurgical Plant in Lipetsk, damaging its oxygen station and oxygen separation unit without causing casualties. The National Guard of Ukraine claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast using an Igla missile. Ukrainian media reported an ATACMS missile destroyed either a S-400 or S-500 missile system, using cluster bombs, at an unknown location in Crimea. Zelenskyy announced the release of ten Ukrainian civilians held by Russia, some of whom had been arrested in Belarus and Russian-occupied areas in Ukraine since 2017, following an agreement mediated by the Vatican. A Russian milblogger released images of Russian soldiers using North Korean shells for M-46 howitzer, written on some of the shells was "for Sevastopol".
Sources: en.wikipedia.org
Trimeperidine, sold under the brand name Promedol, is an opioid analgesic that is an analogue of prodine. It was developed in the early 1950s in the Soviet Union during research into the related drug pethidine. Trimeperidine has four structural isomers, of which two are active, the γ isomer trimeperidine, and the β isomer isopromedol. It is around half the potency of morphine as an analgesic, and has been widely used for the treatment of pain. Trimeperidine produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting, and respiratory depression, which may be harmful or fatal. Trimeperidine is in Schedule I of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9646 with an annual aggregate manufacturing quota of 2 grams as of 2014. The free base conversion ratio for salts includes 0.883 for the hydrochloride. Trimeperidine increases the activity of the reticular activating system in the brain. It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion, as is morphine or heroin. Promedol is included into the standard medication kit, which is carried on the battlefield by every Russian military personnel, as a pain-killer in case wounding.
== Further reading == Behre HM, Nieschlag E, Nieschlag E, Behre HM, Nieschlag S (26 July 2012). "Testosterone preparations for clinical use in males". In Nieschlag E, Behre HM, Nieschlag S (eds.). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 309–335. doi:10.1017/CBO9781139003353.016. ISBN 978-1-107-01290-5. Byrne MM, Nieschlag E (2017). "Androgens: Pharmacological Use and Abuse". Reference Module in Neuroscience and Biobehavioral Psychology. doi:10.1016/B978-0-12-809324-5.03356-3. ISBN 978-0-12-809324-5.{{cite journal}}: CS1 maint: periodical has ISBN (link)
A graphene-based implant on the surface of mouse brains, in combination with a two-photon microscope, is shown to capture high-resolution information on neural activity at depths of 250 micrometers. A review of genetic data from 21 studies with nearly one million participants finds more than 50 new genetic loci and 205 novel genes associated with depression, opening potential targets for drugs to treat depression. The Upano Valley sites are reported as the oldest Amazonian cities built over 2500 years ago, with a unique "garden urbanism" city design. A study presents results of a Riyadh-based trial of eight urban heat mitigation scenarios, finding large cooling effects with combinations that include reflective rooftop materials, irrigated greenery, and retrofitting. 12 January Global warming: 2023 is confirmed as the hottest year on record by several science agencies. NASA reports a figure of 1.4 degrees Celsius above the late 19th century average, when modern record-keeping began. NOAA reports a figure of 1.35 degrees Celsius. Berkeley Earth reports a figure of 1.54 degrees Celsius. An AI-based study shows for the first time that fingerprints from different fingers of the same person share strong detectable similarities. 13 January – NASA fully opens the recovered container with samples from the Bennu asteroid, after three months of failed attempts. 16 January – The first successful cloning of a rhesus monkey is reported by scientists in China.
Baritosis, a benign pneumoconiosis is associated with inhalation of dust containing barium sulfate or barium carbonate; the effects are reversible. Silver poisoning, like lithium poisoning, arises from misapplication of medications. A dramatic symptom of "argyria" is that the skin turns blue or bluish-grey. Thallium poisoning has been observed on several occasions, and it is well known that thallium compounds are highly toxic. Nonetheless, incidents of thallium poisoning are few. Tin poisoning from tin metal, its oxides, and its salts are "almost unknown"; on the other hand certain organotin compounds are almost as toxic as cyanide. Such organotin compounds were once widely used as anti-fouling agents.
==== Molecular interaction of AAS with androgen receptors ==== Anabolic steroids interact with ARs across various tissues, including muscle, bone, and reproductive systems. Upon binding to the AR, anabolic steroids trigger a translocation of the hormone-receptor complex to the cell nucleus, where they either alter gene expression or activate cellular signaling pathways; this results in increased protein synthesis, enhanced muscle growth, and reduced muscle catabolism. Anabolic steroids influence cellular differentiation while favoring the development of muscle cells over fat-storage cells. Research in this field has shown that structural modifications in anabolic steroids are critical in determining their binding affinity to ARs and their resulting anabolic and androgenic activities. These modifications affect a steroid's ability to influence gene expression and cellular processes, highlighting the complex biophysical interactions of anabolic steroids at the cellular level.
Sources: en.wikipedia.org
Bacitracin interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, and a related molecule known as bactoprenol pyrophosphate; both of these lipids function as membrane carrier molecules that transport the building-blocks of the peptidoglycan bacterial cell wall outside of the inner membrane.
==== A-ring reductases (5alpha- and 5beta-reductases) ==== Cortisol is also metabolized irreversibly into 5-alpha tetrahydrocortisol (5-alpha THF) and 5-beta tetrahydrocortisol (5-beta THF), reactions for which 5-alpha reductase and 5-beta-reductase are the rate-limiting factors, respectively. 5-Beta reductase is also the rate-limiting factor in the conversion of cortisone to tetrahydrocortisone.
A 2005 meta-analysis of drug company data found no evidence that SSRIs increased the risk of suicide; however, important protective or hazardous effects could not be excluded. A 2005 review observed that suicide attempts are increased in those who use SSRIs as compared to placebo and compared to therapeutic interventions other than tricyclic antidepressants. No difference risk of suicide attempts was detected between SSRIs versus tricyclic antidepressants. A 2006 review suggests that the widespread use of antidepressants in the new "SSRI-era" appears to have led to a highly significant decline in suicide rates in most countries with traditionally high baseline suicide rates. The decline is particularly striking for women who, compared with men, seek more help for depression. Recent clinical data on large samples in the US, too, have revealed a protective effect of antidepressants against suicide. A 2006 meta-analysis of randomized controlled trials suggests that SSRIs increase suicide ideation compared with placebo. However, the observational studies suggest that SSRIs did not increase suicide risk more than older antidepressants. The researchers stated that if SSRIs increase suicide risk in some patients, the number of additional deaths is small because ecological studies have generally found that suicide mortality has declined (or at least not increased) as SSRI use has increased. An additional meta-analysis by the FDA in 2006 found an age-related effect of SSRIs. Among adults younger than 25 years, results indicated that there was a higher risk for suicidal behavior.
The original liquid formulation without EDTA was returned to the market in the US in May 2008. In 2009, Genzyme acquired the rights to Leukine from Bayer, including the manufacturing facility in the Seattle area. In March 2018 the label was extended to use as a countermeasure for acute radiation syndrome. In February 2018, Partner Therapeutics, Inc. acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.
Seymour Benzer in the late 1950s had developed an assay using phage mutations which provided the first detailed linearly structured map of a genetic region. Crick felt he could use mutagenesis and genetic recombination phage to further delineate the nature of the genetic code. In the Crick, Brenner et al. experiment, using these phages, the triplet nature of the genetic code was confirmed. They used frameshift mutations and a process called reversions, to add and delete various numbers of nucleotides. When a nucleotide triplet was added or deleted to the DNA sequence the encoded protein was minimally affected. Thus, they concluded that the genetic code is a triplet code because it did not cause a frameshift in the reading frame. They correctly concluded that the code is degenerate (multiple triplets can correspond to a single amino acid) and that each nucleotide sequence is read from a specific starting point.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.